Anti-Mouse CD40 – Biotin
Anti-Mouse CD40 – Biotin
Product No.: C2827
- -
- -
Clone FGK45 Target CD40 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Bp50, TNFRSF5 Isotype IgG2a Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Immunogen Recombinant Mouse CD40 Fusion Protein Product Concentration 0.5 mg/ml Formulation This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829588 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this FGK45 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone FGK45 recognizes an epitope on mouse CD40. Background CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis. Antigen Distribution CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors. Ligand/Receptor CD154 (CD40L) PubMed NCBI Gene Bank ID UniProt.org References & Citations1. Grewall, I. S. et al. (1996) Science 73:1864
2. Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569
3. Armitage, R. J. et al. (1993) J. Immunol. 150:3671
4. Pullen, S. S. et al. (1999) Biochemistry 38:10168 Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
C2824 | |
C2825 | |
C2827 | |
C2826 |
Formats Available
- -
- -
Prod No. | Description |
---|---|
C2828 | |
C2829 | |
C2824 | |
C2825 | |
C2827 | |
C2826 | |
F1195 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.